NCT07684924 Early Ga-68 FAPI PET/MR After Acute Myocardial Infarction
| NCT ID | NCT07684924 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara University |
| Condition | Acute Myocardial Infarction (AMI) |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-07-01 |
| Primary Completion | 2028-06-29 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2026-07-01 with a primary completion date of 2028-06-29.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute myocardial infarction (AMI) initiates a complex myocardial repair process involving inflammation, fibroblast activation, and extracellular matrix remodeling, which may ultimately lead to adverse left ventricular remodeling and impaired cardiac function. Fibroblast activation protein (FAP)-targeted positron emission tomography (PET) enables noninvasive visualization of activated fibroblasts and may provide an early imaging biomarker of myocardial remodeling. This prospective single-center observational study aims to evaluate myocardial fibroblast activation using Ga-68 FAPI PET/MR performed approximately 10 ± 2 days after AMI and to investigate its association with subsequent left ventricular remodeling. Serial cardiac magnetic resonance (CMR) examinations will be performed at 3 and 6 months to assess changes in ventricular function and remodeling. The study will investigate whether early myocardial FAPI uptake is associated with subsequent structural and functional changes detected by CMR and evaluate the potential role of Ga-68 FAPI PET/MR as an imaging biomarker for post-infarction remodeling.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years. * Diagnosis of acute myocardial infarction according to current guideline criteria. * Successful coronary revascularization when clinically indicated. * Ability to undergo FAPI PET/MR. * Written informed consent. Exclusion Criteria: * Contraindications to MRI (e.g., non-MR-compatible implanted devices, severe claustrophobia). * Pregnancy or breastfeeding. * Severe renal impairment precluding gadolinium administration (if contrast-enhanced MR is performed). * Inability to provide informed consent. * Any condition considered by the investigator to interfere with study participation.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07684924 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Acute Myocardial Infarction (AMI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07684924 currently recruiting?
Yes, NCT07684924 is actively recruiting participants. Contact the research team at ozkanelgin@yahoo.com for enrollment information.
Where is the NCT07684924 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye).
Who is sponsoring the NCT07684924 clinical trial?
NCT07684924 is sponsored by Ankara University. The trial plans to enroll 25 participants.